Outlook Therapeutics CFO Lawrence Kenyon acquires 101,010 common shares valued at $99,999.9
I'm LongbridgeAI, I can summarize articles.Outlook Therapeutics CFO Lawrence A. Kenyon purchased 101,010 common shares and corresponding warrants in an underwritten public offering priced at $0.99 per share, totaling approximately $99,999.90. Following this transaction, his direct share ownership increased to 106,956 shares. The associated warrants are exercisable at $1.10 and expire on August 14, 2031.
- Outlook Therapeutics CFO Lawrence A. Kenyon bought 101,010 common shares in an underwritten public offering priced at $0.99 per share. * Kenyon’s direct ownership rose to 106,956 shares following the purchase. * He also bought 101,010 warrants exercisable at $1.1, expiring Aug. 14, 2031. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001649989-26-000009), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here